• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pfizer (NY: PFE )

    29.71 -0.32 (-1.07%)
    Official Closing Price Updated: 7:00 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 47,280,804
    Open 29.91
    Bid (Size) 29.77 (7)
    Ask (Size) 29.79 (1)
    Prev. Close 30.03
    Today's Range 29.63 - 30.69
    52wk Range 25.20 - 37.80
    Shares Outstanding 5,606,688,356
    Dividend Yield 5.52%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
    Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
    Via Benzinga
    COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
    Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept. 
    Via Benzinga
    Exposures COVID-19

    Performance

    YTD
    -0.07%
    -0.07%
    1 Month
    +10.12%
    +10.12%
    3 Month
    +16.88%
    +16.88%
    6 Month
    +5.54%
    +5.54%
    1 Year
    -18.02%
    -18.02%

    More News

    Read More
    Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
    Via Benzinga
    VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
    Via Benzinga
    Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
    Via Benzinga
    Pfizer, Cisco, Arch Capital And More: CNBC's 'Final Trades'
    Via Benzinga
    7 Hated Stocks Set to Make a Major Comeback This Year
    Via InvestorPlace
    Alnylam Stock Is a Blockbuster Biopharma In the Making
    Via InvestorPlace
    Decoding Pfizer's Options Activity: What's the Big Picture?
    Via Benzinga
    Time to Pounce: 2 Beaten-Down Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought Right Now
    Via The Motley Fool
    Current Analysis: Pfizer Inc.
    Via Talk Markets
    European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
    Via Benzinga
    Exposures COVID-19
    Pfizer And Roche Advance On Their Weight Loss Drug Journeys
    Via Benzinga
    3 Under $50 Stocks to Buy Now: Q3 Edition
    Via InvestorPlace
    Forget Medical Properties Trust: This High-Yielding Dividend Stock Is a Much Better Buy
    Via The Motley Fool
    7 High-Yield Dividend Stocks Beating Inflation
    Via InvestorPlace
    Topics Economy
    Exposures Interest Rates
    Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
    Via Benzinga
    Positive News is Driving This Cancer Drug Maker’s Stock Higher
    Via MarketBeat
    The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
    Via InvestorPlace
    2 Pharma Stocks to Buy Hand Over Fist This Month
    Via The Motley Fool
    Inflation Drop Fuels Rate Cut Speculation, Investors Shift To Sector Laggards, Russell 2000 Surges Over 3.6%: This Week In The Markets
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
    Via Talk Markets
    With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
    Via Benzinga
    Pfizer, L3Harris Technologies And More: CNBC's 'Final Trades'
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.